Professor Anders H. Lund is the new Director of BRIC
The new director of BRIC, University of Copenhagen, are starting July 1 this year. The new director will be Anders H. Lund, who has been interim director since June last year, where he took over from professor Kristian Helin.
Professor Anders H. Lund will be the new director at the Biotech Research and Innovation Centre (BRIC). He will officially be starting from 1 July 2019.
“For a long time Anders H. Lund has been an important part of BRIC’s history and development and he very much represents BRIC’s focus on excellence, innovation and professional standard. In addition he is well-liked and a present leader with a great understanding of BRIC’s special culture, community and development and with that a natural choice for the job. I look forward to working together with Anders and together with the remaining SUND I look forward to watch BRIC carry on with the positive development,” says Dean Ulla Wewer.
Anders H. Lund has been a group leader at BRIC since 2004. I June last year he was appointed interim director and from July 1 this year he will be director after an international search and hiring process. He will be the director for the coming five years with the possibility of three years of administrative extension. He is following professor Kristian Helin, which had been director of BRIC since 2003 and founded the center.
"I am both proud and honored to have been trusted with this position. My vision for the future of BRIC is to continue to strengthen the four pillars of excellence that makes BRIC an elite research center: Science, people, technology and scientific culture and to deliver education and teaching at the highest level. Our goal must be to develop both excellent science and excellent scientists who are not afraid to ask the big and daring questions, says Anders H. Lund.
From 2011 to 2017 he was the Director of the PhD Graduate Program Molecular Mechanisms of Disease. From 2014 to 2019 he was Head of the PhD Career Program (PCAP), Faculty of Health and Medical Sciences. He has also led European PhD programs and a large national technology platform program.
His scientific focus areas are cancer biology with emphasis on molecular mechanisms behind the development of cancer, including translational control, non-coding RNA and Ribosome biology.